The present invention relates to a liquid composition for enriching aqueous or hydro-alcoholic food, cosmetic and/or dermatological products. The invention also relates to the use of said liquid composition and to the method for producing said liquid composition.

An oral rehydration composition comprising the following: 1-glutamic acid in a range of about 0.01% to about 0.40% w/w and monosodium glutamate in a range of about 0.05% to about 0.80% w/w; about 1.50% w/w glucose monohydrate; about 0.20% w/w sodium chloride; about 0.15% w/w potassium chloride; about 0.35% w/w glycine; about 0.30% w/w trisodiumcitrate; about 0.15% w/w sodium dihydrogen phosphate; about 0.10% w/w xanthan gum; 85% Steviol Glycoside extract in a range of about 0.01% to about 0.03% w/w; about 0.20% w/w citric acid monohydrate; hydrolyzed whey in a range of about 0.15% to about 1.00% w/w; about 1.00% w/w hydrolyzed wheat; comprises cereals as a protein source; comprises enzyme co-factors; comprises a monosaccharide. The oral rehydration composition can be used on humans or animals that suffer from diarrhea.

An oral rehydration composition comprising the following: 1-glutamic acid in a range of about 0.01% to about 0.40% w/w and monosodium glutamate in a range of about 0.05% to about 0.80% w/w; about 1.50% w/w glucose monohydrate; about 0.20% w/w sodium chloride; about 0.15% w/w potassium chloride; about 0.35% w/w glycine; about 0.30% w/w trisodiumcitrate; about 0.15% w/w sodium dihydrogen phosphate; about 0.10% w/w xanthan gum; 85% Steviol Glycoside extract in a range of about 0.01% to about 0.03% w/w; about 0.20% w/w citric acid monohydrate; hydrolyzed whey in a range of about 0.15% to about 1.00% w/w; about 1.00% w/w hydrolyzed wheat; comprises cereals as a protein source; comprises enzyme co-factors; comprises a monosaccharide. The oral rehydration composition can be used on humans or animals that suffer from diarrhea.

A method for treating autoimmune and/or inflammatory diseases includes a step of identifying a subject having a gastrointestinal autoimmune/inflammatory disease. A fasting mimicking diet (FMD) is administered to the subject for a first time period.

A method for treating autoimmune and/or inflammatory diseases includes a step of identifying a subject having a gastrointestinal autoimmune/inflammatory disease. A fasting mimicking diet (FMD) is administered to the subject for a first time period.

The present invention relates to a composition comprising Cricket or an extract thereof for improving a bowel movement function or weight loss.

Disclosed is a composition comprising an effective amount of a dietary metal and a coordinating ligand, wherein the dietary metal is provided as a cationic complex and/or as an anionic complex and wherein the coordinating ligand coordinates the dietary metal cationic complex and/or the dietary metal anionic complex. The composition is used to deliver a dietary metal to a subject in need thereof by administering the composition to the subject, optionally perorally. Examples of the dietary metal include zinc (Zn), copper (Cu), magnesium (Mg), manganese (Mn), iron (Fe), cobalt (Co) and combinations thereof. In a particular example, the coordinating ligand comprises cellulose.

Disclosed is a composition comprising an effective amount of a dietary metal and a coordinating ligand, wherein the dietary metal is provided as a cationic complex and/or as an anionic complex and wherein the coordinating ligand coordinates the dietary metal cationic complex and/or the dietary metal anionic complex. The composition is used to deliver a dietary metal to a subject in need thereof by administering the composition to the subject, optionally perorally. Examples of the dietary metal include zinc (Zn), copper (Cu), magnesium (Mg), manganese (Mn), iron (Fe), cobalt (Co) and combinations thereof. In a particular example, the coordinating ligand comprises cellulose.

Disclosed are nutritional compositions including human milk oligosaccharides that can be administered to individuals including preterm infants, infants, toddlers, and children for improving gastrointestinal function and tolerance, as well as the growth of beneficial bacteria. Additional suitable methods of using the nutritional compositions including the human milk oligosaccharides are also disclosed.

Disclosed are nutritional compositions including human milk oligosaccharides that can be administered to individuals including preterm infants, infants, toddlers, and children for improving gastrointestinal function and tolerance, as well as the growth of beneficial bacteria. Additional suitable methods of using the nutritional compositions including the human milk oligosaccharides are also disclosed.